Short answer: when a team says, “We’ll try 510(k),” it usually means the regulatory strategy is not fully developed.
A 510(k) is not something you “try.” It is something you qualify for.
Under the framework of the U.S. Food and Drug Administration, the 510(k) pathway depends on a very specific standard: substantial equivalence to a legally marketed predicate device.
If that logic is not solid, the pathway collapses.
Short answer: the real difference between 510(k), De Novo, and PMA is not speed. It is risk tolerance.
Each pathway reflects how much uncertainty the U.S. Food and Drug Administration is willing to accept—and how much evidence they require to reduce that uncertainty.
Short answer: an FDA regulatory pathway is not just a compliance decision. It is a portfolio risk signal. For investors, the difference between 510(k), De Novo, and PMA is not technical—it’s financial. Each pathway signals a different level of timeline risk, capital intensity, and probability of return. Understanding that signal changes how smart investors allocate […]
Direct answer: choosing the wrong FDA pathway does not just delay your launch. It can add millions in cost, years in delay, and materially reduce company valuation.
Most pathway mistakes happen early—when teams assume a 510(k) is viable without fully pressure-testing risk, intended use, or technological differences.
Short answer: incorrect FDA pathway assumptions don’t usually fail at the beginning. They fail when investors start asking hard questions.
Early on, optimism hides regulatory gaps. During investor diligence, those gaps get exposed.
That’s because regulatory pathway decisions—510(k), De Novo, or PMA—are not just technical. They define your timeline, capital needs, and exit strategy.
Straight answer: device classification controls how much evidence you must generate—and that controls how fast (or slow) you reach market.
If you don’t understand your classification early, your timeline is not a plan. It’s a guess.
Under the framework of the U.S. Food and Drug Administration, medical devices are placed into three risk-based classes: Class I, Class II, and Class III. The higher the risk, the heavier the evidence burden—and the longer the timeline.
Short answer: the FDA regulatory pathway for medical devices depends on risk, intended use, and whether a similar device already exists.
The three main pathways are:
510(k) – for devices that are substantially equivalent to an existing legally marketed device
De Novo – for novel, low-to-moderate risk devices with no predicate
Hard reality: experienced investors can tell—often within minutes—when regulatory strategy was bolted on late instead of built in early. You don’t need to say “we figured out regulatory later.” It shows up everywhere: in your data, your timelines, your budget, and your answers during diligence. The Diligence Red Flags Investors Immediately Recognize1. Vague or Shifting […]
Simple truth: small regulatory misalignments early in development don’t stay small. They compound—quietly at first, then catastrophically—into six- and seven-figure problems later. Most medical device cost overruns are not caused by bad engineering. They are caused by early FDA misalignment that went unnoticed or unchallenged. How Small Misalignments Snowball Into Big Losses1. A Slightly Off […]
